STAT+: What does Akeso’s primo plenary spot say about its survival data?

This is the online version of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox.

I’m suffering from spring allergies + a nasty head cold this week. Not fun.

Mystery cloaks an ASCO plenary lung cancer survival result

The runup to next month’s annual meeting of the American Society of Clinical Oncology has started, and a good bit of the Wall Street chatter and speculation is centered on the Akeso-Summit Therapeutics drug ivonescimab.

Continue to STAT+ to read the full story…